 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
18 September 2001 | Volume 135 Issue 6 | Pages 393-400
Background: An elevated international normalized ratio (INR) increases the risk for major hemorrhage during warfarin therapy. Optimal management of patients with asymptomatic elevations in INR is hampered by the lack of understanding of the time course of INR decay after cessation of warfarin therapy.
Objective: To identify predictors of the rate of INR normalization after excessive anticoagulation.
Design: Retrospective cohort study.
Setting: Outpatient anticoagulant therapy unit.
Patients: Outpatients with an INR greater than 6.0 were identified from August 1993 to September 1998. Patients in whom two doses of warfarin were withheld and a follow-up INR was obtained on the second calendar day were enrolled. No patient received vitamin K1.
Measurements: The INR was measured 2 days after an INR greater than 6.0 was recorded.
Results: Of 633 study patients with an initial INR greater than 6.0, 232 (37%) still had an INR of 4.0 or greater after two doses of warfarin were withheld. Patients who required larger weekly maintenance doses of warfarin were less likely to have an INR of 4.0 or greater on day 2 (adjusted odds ratio per 10 mg of warfarin, 0.87 [95% CI, 0.79 to 0.97]). Other risk factors for having an INR of 4.0 or greater on day 2 included age (odds ratio per decade of life, 1.18 [CI, 1.01 to 1.38]), index INR (odds ratio per unit, 1.25 [CI, 1.14 to 1.37]), decompensated congestive heart failure (odds ratio, 2.79 [CI, 1.30 to 5.98]), and active cancer (odds ratio, 2.48 [CI, 1.11 to 5.57]).
Conclusions: Steady-state warfarin dose, advanced age, and extreme elevation in INR are risk factors for prolonged delay in return of the INR to within the therapeutic range. Decompensated congestive heart failure and active cancer greatly increase this risk.
Author and Article Information
From Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and Kaiser Permanente Medical Care Program (Northern California), Oakland, and University of California, San Francisco, San Francisco, California.
Acknowledgments: The authors thank Lori Henault, MPH, and Lynn Oertel, RN, for help with data collection; YuChiao Chang, PhD for statistical expertise; and the nurses working in the Anticoagulant Therapy Unit, Massachusetts General Hospital, for their dedication to the care of patients and to the maintenance of a high-quality clinical database.
Grant Support: By Public Health Services research grant AG15478 from the National Institutes of Health and the Eliot B. Shoolman Fund of the Massachusetts General Hospital.
Requests for Single Reprints: Elaine M. Hylek, MD, MPH, General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, MA 02114.
Current Author Addresses: Drs. Hylek, Regan, and Singer: General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, MA 02114.
Dr. Hughes: Bulfinch Medical Group, Massachusetts General Hospital, Founders Building, 3rd Floor, 15 Parkman Street, Boston, MA 02114.
Dr. Go: Division of Research, Kaiser Permanente of Northern California, 3505 Broadway Street, 12th Floor, Oakland, CA 94611-5714.
Dr. Skates: Biostatistics Center, Massachusetts General Hospital, 50 Staniford Street, 5th Floor, Boston, MA 02114.
Author Contributions: Conception and design: E.M. Hylek, R.A. Hughes.
Analysis and interpretation of the data: E.M. Hylek, S. Regan, A.S. Go, D.E. Singer, S.J. Skates.
Drafting of the article: E.M. Hylek.
Critical revision of the article for important intellectual content: E.M. Hylek, A.S. Go, R.A. Hughes, D.E. Singer, S.J. Skates.
Final approval of the article: E.M. Hylek, A.S. Go.
Provision of study materials or patients: R.A. Hughes.
Statistical expertise: E.M. Hylek, S. Regan, D.E. Singer, S.J. Skates.
Obtaining of funding: D.E. Singer.
Administrative, technical, or logistic support: R.A. Hughes, D.E. Singer.
Collection and assembly of data: E.M. Hylek, S. Regan, D.E. Singer. ARTICLE
Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  B. F. McBride The Emerging Role of Antiarrhythmic Compounds With Atrial Selectivity in the Management of Atrial Fibrillation J. Clin. Pharmacol., March 1, 2009; 49(3): 258 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Friedlander, T. T. Yoshikawa, D. S. Chang, Z. Feliciano, and C. Scully Atrial Fibrillation: Pathogenesis, Medical-Surgical Management and Dental Implications J Am Dent Assoc, February 1, 2009; 140(2): 167 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Garcia and E. Hylek Factors in Warfarin Therapy Discontinuation--Reply Arch Intern Med, September 22, 2008; 168(17): 1933 - 1933. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 160S - 198S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation Circulation, May 29, 2007; 115(21): 2689 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, A. Vahanian, H. Baumgartner, J. Bax, E. Butchart, R. Dion, G. Filippatos, F. Flachskampf, R. Hall, B. Iung, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology Eur. Heart J., January 26, 2007; (2007) ehl428v1. [Full Text] [PDF]
|
|
|
|
 |
|
 A.-H. Kristoffersen, G. Thue, and S. Sandberg Postanalytical External Quality Assessment of Warfarin Monitoring in Primary Healthcare Clin. Chem., October 1, 2006; 52(10): 1871 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Shermock, J. T. Connor, N. T. Smith, J. M. Fink, and L. Bragg Validity of Criteria Used to Evaluate Fingerstick Devices That Assess International Normalized Ratio Med Decis Making, May 1, 2006; 26(3): 239 - 246. [Abstract] [PDF]
|
|
|
|
|
|
C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression Chest, May 1, 2006; 129(5): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. DeZee, W. T. Shimeall, K. M. Douglas, N. M. Shumway, and P. G. O'Malley Treatment of Excessive Anticoagulation With Phytonadione (Vitamin K): A Meta-analysis. Arch Intern Med, February 27, 2006; 166(4): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. McBride A Preliminary Assessment of the Critical Differences Between Novel Oral Anticoagulants Currently in Development J. Clin. Pharmacol., September 1, 2005; 45(9): 1004 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Garcia, S. Regan, M. Crowther, R. A. Hughes, and E. M. Hylek Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population Chest, June 1, 2005; 127(6): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Elbe and S. W Chang Moxifloxacin-Warfarin Interaction: A Series of Five Case Reports Ann. Pharmacother., February 1, 2005; 39(2): 361 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D Eckhoff, R. J DiDomenico, and N. L Shapiro Initiating Warfarin Therapy: 5 mg versus 10 mg Ann. Pharmacother., December 1, 2004; 38(12): 2115 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Fang, Y. Chang, E. M. Hylek, J. Rosand, S. M. Greenberg, A. S. Go, and D. E. Singer Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation Ann Intern Med, November 16, 2004; 141(10): 745 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 204S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, R. G. Hart, G. A. Wells, P. Petersen, P. J. Koudstaal, A. L. Gullov, B. S. P. Hellemons, B. G. Koefed, and A. Laupacis A Clinical Prediction Rule to Identify Patients With Atrial Fibrillation and a Low Risk for Stroke While Taking Aspirin Arch Intern Med, April 28, 2003; 163(8): 936 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Predicting Sustained High INR After Excessive Warfarin Anticoagulation Journal Watch Cardiology, November 30, 2001; 2001(1130): 10 - 10. [Full Text]
|
|
|
|
 |
|
 Risk Factors for Prolonged Excessive Anticoagulation Journal Watch (General), October 2, 2001; 2001(1002): 3 - 3. [Full Text]
|
|
|
|
|
|
H. I. Bussey Managing Excessive Warfarin Anticoagulation Ann Intern Med, September 18, 2001; 135(6): 460 - 462. [Full Text] [PDF]
|
|
